Range Impact (RNGE) S-1 19 Aug 16 IPO registration Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Vitality Biopharma, Inc.
Entity Central Index Key	1,438,943
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	STVFD
Document Type	S1
Amendment Flag	false
Document Period End Date	Jun. 30, 2016

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Current Assets
Cash	$ 20,481	$ 95,433	$ 389,730
Accounts receivable, net	39,203	30,396	61,595
Inventory	6,470	6,470	8,478
Prepaid Expense and other current assets	3,058	2,500	2,500
Total Assets	69,212	134,799	462,303
Current Liabilities
Accounts payable and accrued liabilities	232,953	244,937	134,007
Accounts payable - related party	13,800	6,900	1,000
Derivative liability	335,802	401,127	1,406,596
Total liabilities	582,555	652,964	1,541,603
Stockholders' Deficiency
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 7,911,708 and 7,296,892 shares issued and outstanding, respectively	10,562	7,912	7,297
Shares issuable, 999,700 shares	100,000	99,970
Additional paid-in-capital	12,332,059	11,890,512	11,288,637
Accumulated deficit	(12,955,964)	(12,516,559)	(12,375,234)
Total stockholders' deficiency	(513,343)	(518,165)	(1,079,300)
Total liabilities and stockholders' deficiency	$ 69,212	$ 134,799	$ 462,303

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Oct. 11, 2011	Oct. 09, 2011
Balance Sheet
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000	1,000,000,000	525,000,000	75,000,000
Common stock, shares issued	10,561,708	7,911,708	7,296,892	51,450,000	7,350,000
Common stock, shares outstanding	10,561,708	7,911,708	7,296,892	51,450,000	7,350,000
Shares issuable (in shares)	588,236	999,700

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement
Revenues	$ 46,377	$ 61,915	$ 248,348	$ 245,680
Cost of goods sold	25,119	24,033	149,478	121,341
Gross profit	21,258	37,882	98,870	124,339
Operating Expenses:
General and Administrative	327,874	741,596	2,196,922	2,749,153
Rent and other related party costs	6,900	10,900	30,600	49,017
Research and development	110,315	183,525	613,119	1,131,327
Total Operating Expenses	445,089	936,021	2,840,641	3,929,497
Loss from operations	(423,831)	(898,139)	(2,741,771)	(3,805,158)
Other income (expenses)
Cost to induce exercise of warrants				(961,767)
Interest expense	(621)	(68)	(363)	(6,065)
Change in fair value of derivative liability	(14,953)	1,113,801	2,600,809	724,617
Total other income (expense)	(15,574)	1,113,733	2,600,446	(243,215)
Net loss	$ (439,405)	$ 215,594	$ (141,325)	$ (4,048,373)
Loss per share - Basic and diluted			$ (0.02)	$ (0.57)
Net income (loss) per common share - basic	$ (0.04)	$ 0.03
Net income (loss) per common share - diluted	$ (0.04)	$ 0.03
Weighted average number of common shares outstanding, basic and diluted			7,541,984	7,042,188
Weighted average number of common shares outstanding, basic	10,069,358	7,568,760
Weighted average number of common shares outstanding - diluted	10,069,358	7,778,760

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Common Stock, Issuable [Member]	Unvested, Issued Common Stock [Member]	Total
Balance, amount at Mar. 31, 2014	$ 6,683	$ 8,359,516	$ (8,326,861)		$ (149,714)	$ (110,376)
Balance, shares at Mar. 31, 2014	6,683,252
Reclassication of unvested, issued common stock to paid-in capital		(149,714)			$ 149,714
Common stock issued upon exercise of options, value	$ 5	4,995				$ 5,000
Common stock issued upon exercise of options, shares	5,000					5,000
Common stock issued to employees with vesting terms, value	$ 150	329,361				$ 329,511
Common stock issued to employees with vesting terms, shares	150,000
Common stock issued for services, value	$ 91	338,809				338,900
Common stock issued for services, shares	90,992
Fair value of vested stock options		233,310				233,310
Fair value of vested warrants granted to employees		432,772				432,772
Common stock issued upon exercise of warrants, value	$ 368	1,470,220				1,470,588
Common stock issued upon exercise of warrants, shares	367,648
Extinguishment of derivative liability		269,368				269,368
Net Loss			(4,048,373)			(4,048,373)
Balance, amount at Mar. 31, 2015	$ 7,297	11,288,637	(12,375,234)			(1,079,300)
Balance, shares at Mar. 31, 2015	7,296,892
Amortization of common stock issued to employees with vesting terms		161,936				$ 161,936
Common stock issued upon exercise of options, shares
Common stock issued for services, value	$ 115	275,885				$ 276,000
Common stock issued for services, shares	114,816
Fair value of vested stock options		286,248				286,248
Fair value of vested warrants granted to employees		182,072				182,072
Issuance of stock and warrants, value	$ 500
Issuance of stock and warrants, shares	500,000
Issuance of stock and warrants, APIC		(403,577)				(403,077)
Extinguishment of derivative liability		99,311				99,311
Common stock issuable				$ 99,970		99,970
Net Loss			(141,325)			(141,325)
Balance, amount at Mar. 31, 2016	$ 7,912	11,890,512	(12,516,559)	99,970		(518,165)
Balance, shares at Mar. 31, 2016	7,911,708
Amortization of common stock issued to employees with vesting terms		24,000				24,000
Fair value of vested stock options		39,905				39,905
Fair value of vested warrants granted to employees		35,014				35,014
Issuance of stock and warrants, value	$ 2,650	262,350		(99,970)		165,030
Issuance of stock and warrants, shares	2,650,000
Common stock issued upon exercise of warrants, value						$ 100,000
Common stock issued upon exercise of warrants, shares						588,236
Extinguishment of derivative liability		80,278				$ 80,278
Common stock issuable				100,000		100,000
Net Loss			(439,405)			(439,405)
Balance, amount at Jun. 30, 2016	$ 10,562	$ 12,332,059	$ (12,955,964)	$ 100,000		$ (513,343)
Balance, shares at Jun. 30, 2016	10,561,708

STATEMENTS OF STOCKHOLDERS' EQ6

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) (Parenthetical) - shares	Jun. 30, 2016	Mar. 31, 2016
Statement Of Stockholders' Equity
Shares issuable (in shares)	588,236	999,700

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net income (loss)	$ (439,405)	$ 215,594	$ (141,325)	$ (4,048,373)
Adjustments to reconcile net loss to net cash used in operating activities:
Fair value of vested stock options	39,905	119,764	286,248	233,310
Amortization of common stock issued to employees and director	24,000	59,234
Fair value of vested common stock issued to employees			161,936	329,511
Fair value of vested warrants granted to employees	35,014	77,031	182,072	432,772
Fair value of common stock issued for services		115,000	276,000	338,900
Cost of warrant modification				961,767
Change in fair value of derivative liability	14,953	(1,113,801)	(2,600,809)	(724,617)
Changes in assets and liabilities:
Accounts receivable	(8,807)	18,267	31,199	(22,100)
Inventory			2,008	(8,478)
Advance payment on related party lease		(2,300)		10,413
Prepaid expense and deposit	(558)			8,137
Accounts payable - related party	6,900	(1,000)	5,900	(15,100)
Accounts payable and accrued liabilities	(11,984)	25,801	110,930	4,092
Net Cash Used in Operating Activities	(339,982)	(486,410)	(1,685,841)	(2,499,766)
Investing activities
Acquisition of cash upon acquisition				10,505
Net Cash Provided by Investing Activities				10,505
Financing activities
Proceeds from exercise of warrants, net				1,470,588
Proceeds from exercise of options				5,000
Proceeds from Common Stock issuable	100,000		99,970
Proceeds from sale of common stock and warrants, net	165,030	1,291,574	1,291,574
Net Cash Provided by Financing Activities	265,030	1,291,574	1,391,544	1,475,588
Net increase (decrease) in cash	(74,952)	805,164	(294,297)	(1,013,673)
Cash - Beginning of Period	95,433	389,730	389,730	1,403,403
Cash - End of Period	20,481	1,194,894	95,433	389,730
Cash paid during the period for:
Interest	363	68
Income taxes
Non-Cash Investing and Financing Activities:
Fair value of warrants issued with common stock recorded, as derivative liability		$ 1,694,651	1,694,651	961,767
Extinguishment of derivative liability	$ 80,278		$ 99,311	269,368
Acquisition of accounts receivable upon acquisition				$ 34,495

BUSINESS AND BASIS OF OPERATION

BUSINESS AND BASIS OF OPERATIONS	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
BUSINESS AND BASIS OF OPERATIONS [Abstract]
BUSINESS AND BASIS OF OPERATIONS	1. BUSINESS AND BASIS OF OPERATIONS Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”) was incorporated under the laws of the State of Nevada on June 29, 2007. In December 2015, we discovered novel pharmaceutical applications of our glycosylation technology for producing cannabinoid prodrugs and we have recently changed our operational focus towards pharmaceutical development of the cannabinoid prodrugs. On July 15, 2016, the holders of a majority of our outstanding common stock and our Board of Directors approved 1) a name change whereby our name changed from Stevia First Corp. to Vitality Biopharma, Inc., 2) a reverse split of our outstanding common shares whereby each 10 shares of common stock will be exchanged for 1 share of common stock and 3) an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These changes became effective on July 20, 2016 . All share and per share information contained in this Quarterly Report, including these unaudited condensed financial statements, has been adjusted to reflect these changes as if it had occurred in the earliest period presented.  Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and utilized cash in operations since inception resulting in stockholders’ deficit of $513,343 as of June 30, 2016, and further losses are anticipated in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2016 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the business for the 6 months after June 30, 2016. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations . We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment. Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three months ended June 30, 2016 and 2015 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2016 was derived from the audited financial statements as of and for the year ended March 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 24, 2016. These financial statements should be read in conjunction with that report.	1. BUSINESS AND BASIS OF OPERATIONS Stevia First Corp. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007 and commenced operations as a mineral exploration company. On October 10, 2011, we completed a merger with our wholly-owned subsidiary, Stevia First Corp., whereby we changed our name from “Legend Mining Inc .” to “Stevia First Corp.” Also on October 10, 2011, we effected a seven for one forward stock split of authorized, issued and outstanding common stock. As a result, our authorized capital was increased from 75,000,000 shares of common stock with a par value of $0.001 to 525,000,000 shares of common stock with a par value of $0.001 , and issued and outstanding shares increased from 7,350,000 to 51,450,000 . In February 2012, we substantially changed our management team, and began pursuing an agricultural biotechnology business plan. In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company’s common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000 . These corporate changes became effective on July 20, 2016 and are reflected in these financial statements. The Company's fiscal year end is March 31. Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and has a stockholders’ deficiency of $518,165 as at March 31, 2016, and further losses are anticipated in the development of its business. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate as of March 31, 2016 we will have sufficient funds to operate the business for the next 6 months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, seeking to license or acquire new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. Subsequent to March 31, 2016, we completed a private placement of our common stock and warrants resulting in net proceeds of $265,000 , of which proceeds amounting to $99,970 were received in March 2016. We do not have any other firm commitments for future capital. Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, significant revenue to fund our business from our operations, and will need to obtain most of our necessary funding from external sources in the near term. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property and could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of our outstanding derivative liabilities. Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At June 30, 2016, and March 31, 2016, the allowance for doubtful accounts and returns and discounts was approximately $17,500 . Financial Assets and Liabilities Measured at Fair Value The Company accounts for the fair value of financial instruments in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) topic 820, “Fair Value Measurements and Disclosures” (ASC 820), formerly SFAS No. 157 “Fair Value Measurements”. ASC 820 defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts payable and accrued liabilities, each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The Company uses Level 2 inputs for its valuation methodology for the warrant derivative liabilities as their fair values were determined by using a probability weighted average Black-Scholes-Merton pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. At June 30, 2016 and March 31, 2016, the Company’s balance sheet includes the fair value of derivative liabilities that were measured using level 2 measurements. The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC 815. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2016 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB ASC, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Basic and Diluted Loss Per Share  The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period.  As of June 30, 2016 potentially dilutive securities include options to acquire 892,500 shares of common stock and warrants to acquire 9,702,713 shares of common stock. At June 30, 2015 potentially dilutive securities include options to acquire 830,000 shares of common stock and warrants to acquire 2,502,704 shares of common stock. The basic and fully diluted shares for the three months ended June 30, 2016 are the same because the inclusion of the potential shares would have had an anti-dilutive effect. Diluted net income per common share for the three months ended June 30, 2015 was calculated based on an increased number of shares that would be outstanding as follows:      Three Months Ended June 30,  2016 2015  Numerator:  Net income (loss) $ (439,405) $ 215,594  Denominator:  Weighted average shares outstanding (basic) 10,069,358 7,568,760  Effect of dilutive stock options - 210,000  Weighted average shares outstanding (diluted) 10,069,358 7,778,760  Net income (loss) per share  Basic $ (0.04) $ 0.03  Diluted $ (0.04) $ 0.03   Recent Accounting Pronouncements  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers . ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.  In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases . ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Use of Estimates and Assumptions The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and input assumptions used in the valuation of derivative liabilities.  Revenues Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for products and/or services that have been delivered in the normal course of business, title has passed, the selling price is both fixed and determinable, and collectability is reasonably assured, all of which generally occurs upon shipment of the Company’s product or delivery of the product to the destination specified by the customer. The Company determines whether delivery has occurred based on when title transfers and the risks and rewards of ownership have transferred to the buyer, which usually occurs when the Company ships the products. The Company regularly reviews its customers’ financial positions to ensure that collectability is reasonably assured. Except for warranties, the Company has no post-sales obligations.  Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At March 31, 2016 and 2015, the allowance for doubtful accounts and returns and discounts was approximately $17,500 and $2,500 , respectively. Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:  Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The fair value of the derivative liabilities of $401,127 and $1,406,596 at March 31, 2016 and 2015, respectively, were valued using Level 2 inputs.  The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.  Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2016, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.  Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period. Basic and Diluted Loss Per Share The Company computes loss per share in accordance with ASC Topic 260, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:      March 31,  2016 2015  Options 909,167 632,500  Warrants 2,002,713 1,212,713  Total 2,911,880 1,845,213  Research and Development  Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.  Recent Accounting Pronouncements  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers . ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.  In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  In November 2014, the FASB issued Accounting Standards Update No. 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in ASU 2014-6 do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. ASU 2014-6 applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases . ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

ACQUISITION FROM RELATED PARTY

ACQUISITION FROM RELATED PARTY	12 Months Ended
	Mar. 31, 2016
ACQUISITION FROM RELATED PARTY [Abstract]
ACQUISITION FROM RELATED PARTY	3. ACQUISITION FROM RELATED PARTY  On May 16, 2014, the Company entered into an Asset Purchase Agreement with Percipio Biosciences, Inc. (“Percipio”), a Delaware corporation, to purchase certain assets of Percipio for $50,000 . The Company’s Chief Executive Officer, Robert Brooke, owned 20% of Percipio. The acquisition of the assets has been accounted for as a purchase in accordance with ASC Topic 805 Business Combinations and the assets have been included in the Company’s financial statements since May 16, 2014. The purchase price was allocated to current assets based on their fair value as determined by management. At March 31, 2016, $11,950 of the purchase price remains unpaid and is included in accounts payable on the accompanying balance sheet. The Company has determined that the acquisition is not a material acquisition and accordingly, no pro-forma information has been presented. In conjunction with the Percipio asset purchase, the Company entered into written employment agreement with Dr. Fang Lu, majority owner and President of Percipio, under which he now serves as Senior Scientist for the Company. Dr. Lu’s employment agreement commenced on May 17, 2014 and is terminable at any time at the option of Dr. Lu or the Company. Under the employment agreement, Dr. Lu is entitled to an annual salary of $95,000 .

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
DERIVATIVE LIABILITY [Abstract]
DERIVATIVE LIABILITY	3. DERIVATIVE LIABILITY Under authoritative guidance used by the FASB on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The warrants issued to purchasers and placement agent in June 2013 and September 2014, and the warrants issued to investors in May 2015, do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future or have other variable provisions. The Company was required to include the reset provisions in order to protect the holders of the warrants from the potential dilution associated with future financings, and a fundamental transaction provision, which require a revaluation of the liabilities. In accordance with the FASB authoritative guidance, the warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. As of March 31, 2016 and June 30, 2016, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Warrants:     June 30, 2016 March 31, 2016 Exercise Price $ 2.00 - 4.25 $ 3.00 - 4.50  Stock Price $ 0.50 $ 0.70 Risk-free interest rate 0.48 - 0.86 % 0.19 - 1.04 %  Expected volatility 126.31 % 105.06 - 124.77 % Expected life (in years) 1.25 - 3.9 years 0.1 - 4.2 years  Expected dividend yield 0 0   Fair Value: $ 335,802 $ 401,127  The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration dates of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. Certain warrants included in the March 31, 2016 derivative balance expired in May 2016 and were therefore extinguished from the derivative balance at June 30, 2016. For the three months ended June 30, 2016, the Company recorded an increase in fair value of the derivative liability of $14,953 . As of June 30, 2016, the aggregate fair value of the derivative liabilities was $335,802 .	4. DERIVATIVE LIABILITY T he FASB has issued authoritative guidance whereby instruments which do not have fixed settlement provisions are deemed to be derivative instruments. Certain warrants issued to investors and placement agents (described in Note 5 and Note 6) do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future. In accordance with the FASB authoritative guidance, the warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. At the applicable dates of issuance and as of March 31, 201 5 and March 31, 201 6 , the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:     Date of Modification September 24, 2014 March 31, 2015 Upon Issuance May 11, 2015 March 31, 2016 Exercise Price $ 4.00 – 4.50 $ 3.40 - 4.50 $ 3.50 - 4.50 $ 3.00 – 4.50  Stock Price $ 4.20 $ 3.80 $ 2.90 $ 0.70 Risk-free interest rate 1.78 - 2.0 % 0.41 - 1.25 % 0.17 - 1.59 % 0.19 – 1.04 %  Expected volatility 84.45 % 76.26 % 76.26 - 107.5 % 105.06 - 124.77 % Expected life (in years) 0.01 – 5.0 years 2.50 - 4.5 years 0.75 – 5.0 years 0.1 – 4.2 years  Expected dividend yield 0.00 0.00 0.00 0.00   Fair Value: $ 961,767 $ 1,406,596 $ 1,694,651 $ 401,127   The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.  On September 10, 2014, certain terms of certain of the Company’s warrants were modified in connection with an early exercise offer made to the warrant holders, and the incremental change in their fair values of $21,218 was accounted for as an increase in the fair value of the derivative liabilities as of the date of modification and recorded as a cost to induce exercise of the warrants. Also, as part of the terms of the early exercise offer, the Company issued to such warrant holders new, replacement warrants with an aggregate fair value at their issue date of $940,549 , which was accounted for as a derivative liability at the issue date (described in Note 7). All of the warrants subject to the early exercise offer, which were accounted for as derivative liabilities, were exercised in connection with such offer, and as such their corresponding fair value at the exercise date of $269,368 was extinguished from the derivative liabilities balance. During the year ended March 31, 2015, we recognized a change in fair value of the derivative liability of $724,617 . As of March 31, 2015, the aggregate fair value of the derivative liabilities was $1,406,596 .  In May 2015, we recognized additional derivative liabilities of $1,694,651 related to the warrants issued in conjunction with the sale of the Company’s c ommon stock (described in Note 5 ). For the fiscal year ended March 31, 2016 , the Company reco gnized a change in fair value of the derivative liability of $2,600,809 . As of March 31, 2016 , the aggregate fair value of the derivative liabilities was $401,127 .

STOCKHOLDERS' DEFICIENCY

STOCKHOLDERS' DEFICIENCY	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
STOCKHOLDERS' DEFICIENCY [Abstract]
STOCKHOLDERS' DEFICIENCY	4. EQUITY Equity Financing  In May 2016, the Company entered into a securities purchase agreement providing for the issuance and sale by the Company to the purchasers, in a private placement, of an aggregate of 2,650,000 shares of the Company’s common stock (collectively, the “Shares”) and Warrants to purchase up to an aggregate of 7,950,000 shares of the Company’s common stock,(the “Warrants”, and the shares issuable upon exercise of the Warrants, collectively, the “Warrant Shares”), at a price of $0.10 per Share (the “Offering”). The Warrants have an exercise price of $0.17 per share and expire six months from the date of issuance. The Offering closed on May 4, 2016. The aggregate proceeds to the Company from the sale of the Shares and Warrants was $265,000 .  In addition, 999,700 shares of common stock valued at $99,970 were issued during the period that were previously reflected as common stock, issuable.  Common stock issued to employees for services with vesting terms  The Company has issued shares of common stock to employees and directors that vest over time. These shares of common stock were valued based upon the market price of the Company’s common stock at the dates of grant and determined the aggregate fair values to be of approximately $683,000 . The allocable portion of the aggregate fair values of these shares of common stock that vested during the three months ended June 30, 2016 and 2015 amounted to $24,000 and $59,234 , respectively, and were recognized as an expense in the accompanying statements of operations during the periods then ended. As of June 30, 2016, approximately $43,000 of these awards remains unvested and will be amortized as compensation costs in future years.  Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement.  The following table summarizes restricted common stock activity:     Number of Shares  Non-vested shares, March 31, 2016 175,833  Granted -  Vested (2,500)  Forfeited -  Non-vested shares, June 30, 2016 173,333 	5. STOCKHOLDERS’ DEFICIENCY Equity financing In May 2015, the Company entered into a Securities Purchase Agreement with seven p urchasers for the sale of an of aggregate of 500,000 shares of the Company’s common stock (collectively, the “Shares” ), and warrants to purchase an aggregate of 1,250,001 shares of the Company’s common stock for total gross proceeds of $1,500,000 , or a sales price of $3.00 per share (the “Offering”). The Offering closed on May 11, 2015. The Company incurred $208,426 direct costs, fees and expenses in connection with the Offering, resulting in net cash proceeds to the Company of $1,291,574 . The warrants to purchase an aggregate of 1 , 250 , 00 1 issued to the purchasers in the Offering were issued in three tranches: Series A Warrants to purchase up to an aggregate of 500,000 shares of the Company’ s common stock, with exercise price of $4.50 per share, and a term of 5 years; Series B Warrants to purchase up to an aggregate of 500,000 shares of the Company’s common stock, with exercise price of $3.50 per share, and a term of 9 m onths; and Series C Warrants to purchase up to an aggregate of 250,000 shares of the Company’s common stock , with exe rcise price of $4.00 per share, and a term of 1 year; all of which are exercisable immediately (the Series A Warrants, the S eries B Warrants and the Series C Warrants, collectively, the “Warrants”). The Company also issued warrants to purchase up to 40,000 shares of the Company’s common stock (the “Placement Agent Warrants”) to H.C. Wainwright & Co. , LLC as placement agent to the Offering. The Placement Agent Warrants have an exercise price of $3.75 per share, a term of 5 years, and are exercisable immediately.  The exercise price of the Series A Warrants granted to the purchasers of the Offering incl udes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’ s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercis e or conversion price below the current exercise price of the warrants, provided that the exercise price shall not be reduced to less than $2.00 per share. Additionally, all of the Warrants granted to the purchasers of the Offering and the Placement Agent Warrants are subject to provision for certain fundamental transactions. The Comp any considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” a nd determined that the exercise prices of the Warrants and the Placement Agent Warrants were not fixed amounts because they are subject to fluctuation based on the occurrence of future offerings or events, and certain fundamental transactions. As a result, the Company determined that the Warrants and the Placement Agent Warrants are not considered indexed to the Company’ s own stock and characterized the initial fair value of these warrants as derivative liabilities upon issuance. The Compan y determined the aggregate initial fair value of the Warrants and the Placement Agent Warrants in th e Offering to be $1,694,651 at issuance valued using a probability weighted average Black-Scholes-Merton pricing model. For financial statement purposes, the amount of the derivative liability created from the issuance of the W arrants and the Placement Agent Warrants of $1,694,651 has been offset to the net cash proceeds received of $ 1,291,574 , resulting in a net reduction of additional paid-in capital of $408,077 from the sale of the Shares of common stock and Warrants.  Common stock issued to employees for services with vesting terms The Company has issued the following shares of common stock to employees and directors that vest over time:  · In July and August 2012, the Company issued an aggregate of 70,000 shares of its common stock to employees and a director of the Company, with aggregate fair value of $189,000 at grant date, and vesting over a period ranging from 16 months to 60 months from the date of grant under the Company's stock option and incentive plan (the “2012 Stock Incentive Plan”).  · In July 2013, the Company issued 10,000 shares of its common stock to an employee of the Company with fair value of $36,000 at grant date and vesting over a period of 31 months from the date of grant under the Company's 2012 Stock Incentive Plan.  · In conjunction with the Percipio asset purchase (see Note 3) entered into by the Company on May 2014, the Company entered into an employment agreement with a new employee, pursuant to which the Company granted 10,000 shares of its common stock with fair value of $38,000 at grant date . The 10,000 shares of stock is vesting over a period of 24 months from the date of grant under the Company's 2012 Stock Incentive Plan.  · In conjunction with the Distribution and License Agreements (see Note 9) entered into by the Company in August 2014, the Company entered into employment agreements with two new employees, pursuant to which the Company granted an aggregate of 140 , 000 shares of its common stock , with aggregate fair value of $420,000 at grant date . Of these 1 40 ,000 shares of stock, 40,000 vested immediately, and the remaining 100,000 are vesting over period s ranging from 12 months to 36 months from the date of grant . An aggregate of 100,000 shares of the Company’s restricted common stock will also be issued and will vest upon achievement certain milestones, for which the Company will account for their costs at the time their issuance becomes probable. These shares of common stock were valued based upon the market price of the Company’s common stock at the dates of grant and determined the aggregate fair value s to be of approximately $ 683 ,000 . The allocable portion of the aggregate fair value s of the se shares of common stock that vested during the year s ended March 31, 201 6 and 201 5 amounted to $161,936 and $329,511 , respectively, and were recognized as expense in the accomp anying statements of operations during the years then ended. As of March 31, 201 6 , approximately $86,000 of these awards remains unvested and will be amortized as compensation costs in future years.  Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement. The Company reclassified $149,714 from unvested , unissued common stock to additional paid-in capital relating to the unvested portion of vested shares granted as of the prior year ended March 31, 2014, to make its presentation of stockholders’ deficiency reflect the transaction more appropriately. There was no net effect on stockholders’ deficiency.  Common stock issued for services  During the year ended March 31, 2015 , the Company issued an aggregate of 79,098 shares of the Company’s common stock to consultant s as payment for services and recorded an expense of $ 294,1 00 based on the closing market price of our common stock on the date of the issuance. These shares were issued outside of the 2012 Stock Incentive Plan. In December 2014, the Company issued 7,895 shares of common stock under the 2012 Stock Incentive Plan to a consultant under the terms of a consulting agreement and recorded an expense of $30,000 based on the closing market price of our common stock on the date of issuance.  In March 2015, the Company also issued 4,000 shares of common stock under the 2012 Stock Incentive Plan , to an employee and recorded an expense of $ 14,8 00 based on the closing market price of our common stock on the date of issuance.  In May 2015, pursuant to the terms of certain consulting agreement, the Company issued an aggregate of 32,500 shares of the Company’s common stock to two consultants as payment for services and record ed an expense of $115,000 based on the fair value of the Company’s common stock at the issuance dates. In July 2015, we i ssued a total of 31,000 shares of our common stock to two consultants in exchange for services and recorded an expense of $61,000 . These shares were issued outside of the 2012 Stock Incentive Plan.  In October and November 2015, pursuant to the terms of a certain consulting a greement, the Company issued an aggregate of 51,316 shares of the Company’s common stock to a consultant as payment f or services valued at $100,000 . These shares were issued outside of the 2012 Stock Incentive Plan .

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
STOCK OPTIONS [Abstract]
STOCK OPTIONS	5. STOCK OPTIONS Pursuant to the terms of the 2012 Stock Incentive Plan, the exercise price for all equity awards issued under the 2012 Stock Incentive Plan is based on the market price per share of the Company’s common stock on the date of grant of the applicable award. A summary of the Company’s stock option activity for the three months ended June 30, 2016 is presented below:     Shares Weighted Average Exercise Price  Balance at March 31, 2016 907,500 $ 3.30  Granted - -  Exercised - -  Cancelled (15,000) 3.40  Balance outstanding at June 30, 2016 892,500 $ 2.86  Balance exercisable at June 30,2016 717,501 $ 2.99  At June 30, 2016, options to purchase common shares were outstanding as follows:     Number of options Weighted Average Exercise Price Weighted Average Grant-date Stock Price   Options Outstanding, June 30, 2016 130,000 $ 1.00 $ 10.00  10,000 $ 1.50 $ 0.40  287,500 $ 2.00 - 2.70 $ 2.00 - 2.70  205,000 $ 3.10 - 3.80 $ 3.10 - 3.80  200,000 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  892,500   Options Exercisable, June 30,2016 130,000 $ 1.00 $ 10.00  2,500 $ 1.50 $ 0.40  157,500 $ 2.00 - 2.70 $ 2.00 - 2.70  171,668 $ 3.10 - 3.80 $ 3.10 - 3.80  195,833 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  717,501 During the three months ended June 30, 2016 and 2015, we expensed total stock-based compensation related to vesting stock options of $39,905 and $119,764 , respectively, and the remaining unamortized cost of the outstanding stock options at June 30, 2016 was $263,460 . This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded. The intrinsic values of all outstanding and exercisable stock options at June 30, 2016 were approximately $0 and $0 , respectively, and $130,000 and $130,000 , respectively, at June 30, 2015.	6. STOCK OPTIONS Year Ended March 31, 2015  During the year ended March 31, 2015, the Company granted to employees options to purchase an aggregate of 112,500 shares of the Company’s common stock that expire ten years from the date of grant and have vesting periods ranging from zero to 36 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 81.84 %, (ii) discount rate of 1.62 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $300,000 . During the year ended March 31, 2015, the Company also granted to three consultants options to purchase 22,500 shares of the Company’s common stock that expire between five and ten years from date of grant and have vesting periods ranging from is 0 to 36 months. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 76.26 %, (ii) discount rate of 2.17 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The total fair value of the option grants to the consultants at their grant dates was approximately $88,000 . In April 2014, 5,000 options were exercised by a consultant at an exercise price of $1.00 per share or total proceeds to the Company of $5,000 .  Year Ended March 31, 201 6  During the year ended March 31, 2016, the Company granted to employees options to purchase an aggregate of 137,500 shares of the Company’s common stock that expire ten years from the date of grant and have vesting periods ranging from zero to 36 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 76.26 %, (ii) discount rate of 2.19 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $233,000 . During the year ended March 31, 2016, the Company also granted to five consultants options to purchase 140,000 shares of the Company’s common stock that expire between three and ten years from date of grant and have vesting periods ranging from is 0 to 36 months. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate between 76.26 % to 107.51 %, (ii) discount rate of 2.17 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The total fair value of the option grants to the consultants at their grant dates was approximately $131,000 . A summary of the Company’s stock option activity during the fiscal years ended March 31, 2015 and 2016 is as follows:      Shares Weighted Average Exercise Price  Balance at March 31, 2014 515,000 $ 2.60  Granted 135,000  Exercised (5,000)  Cancelled (12,500)  Balance outstanding at March 31, 2015 632,500 $ 3.30  Granted 275,000  Exercised -  Cancelled -  Balance outstanding at March 31, 2016 907,500 $ 3.30  Balance exercisable at March 31,2016 679,376 $ 3.20  A summary of the Company’s stock options outstanding as of March 31, 2016 is as follows:    Number of Options Weighted Average Exercise Price Weighted Average Grant-date Stock Price  Options Outstanding, March 31, 2016 130,000 $ 1.00 $ 10.00  10,000 1.50 1.50  287,500 $ 2.00 - 2.70 $ 2.00 - 2.70  220,000 $ 3.10 - 3.80 $ 3.10 - 3.80  199,167 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  907,500  Options Exercisable, March 31, 2016 130,000 $ 1.00 $ 10.00  123,750 $ 2.00 - 2.70 $ 2.00 - 2.70  171,667 $ 3.10 - 3.80 $ 3.10 - 3.80  193,959 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  679,376 During the years ended March 31, 2016 and 2015, we expensed total stock-based compensatio n related to stock options of $286,248 and $233,310 , respectively, and the remaining unamortized cost of the outstanding stock-based awards at March 31, 2016 was approximately $345,000 . This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded. The outstanding stock o ptions had no intrinsic value at March 31, 201 6.

WARRANTS

WARRANTS	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
WARRANTS [Abstract]
WARRANTS	6. WARRANTS At June 30, 2016, warrants to purchase common shares were outstanding as follows:     Shares Weighted Average Exercise Price  Balance at March 31, 2016 2,002,718 $ 3.50  Granted 7,950,000 0.17  Exercised - -  Expired (250,000) $ 4.00  Balance outstanding and exercisable at June 30, 2016 9,702,718 $ 0.55    Warrants issued in equity financing In May 2016, the Company entered into a securities purchase agreement with the purchasers identified therein providing for the issuance and sale by the Company to the purchasers, in a private placement, of an aggregate of 2,650,000 and Warrants to purchase up to an aggregate of 7,950,000 shares of the Company’s common stock. The Warrants have an exercise price of $0.17 per share and originally expired November 4, 2016. On August 16, 2016, the Company and the purchasers extended the warrant expiration date to February 4, 2017. The change in the fair value of the warrants due to this modification was estimated to be approximately $194,000 and will be expensed on the date modified.  Warrants issued to employees  On August 25, 2014, we entered into employment agreements with two new employees, pursuant to which, these employees became entitled to receive warrants to purchase an aggregate of 440,000 shares of the Company’s common stock as discussed in Note 8. These warrants have an exercise price of $3.00 , and a term of ten years from issue date. Vesting terms of these warrants are as follows: (i) warrants to purchase 80,000 shares of common stock vested immediately at their grant date with a fair value of $201,680 , which was recorded as an expense during the year ended March 31, 2015, (ii) warrants to purchase 200,000 shares of common stock have vesting terms ranging from one year to three years with a fair value of $504,204 upon grant date, which is being amortized over their vesting terms, of which $ 35,014 were recorded as an expense during the three months ended June 30, 2016, and (iii) warrants to purchase 160,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement (See Note 8). The remaining unamortized cost of the outstanding warrants at June 30, 2016 was approximately $21,000 . The aggregate intrinsic value of all of the outstanding and exercisable warrants at June 30, 2016 and March 31, 2016 was approximately $2,623,500 and $0 , respectively.  Cash received in advance of exercise of warrants  During the three months ended June 30, 2016, the Company received $100,000 of proceeds from holders of warrants to acquire 588,236 shares of common stock. As of June 30, 2016, the Company has not yet received the notice of exercise from the holders, and therefore, had not issued the shares of stock and had reflected the $100,000 proceeds received as common stock issuable in the Company’s condensed statement of stockholders’ deficit herein.	7. WARRANTS A summary of warrants to purchase common stock issued during the fiscal years ended March 31, 2015 and 2016 is as follows:      Shares Weighted Average Exercise Price  Balance outstanding at March 31, 2014 772,717 $ 4.10  Granted 807,648 3.70  Exercised (367,647) 4.00  Cancelled - -  Balance outstanding at March 31, 2015 1,212,718 $ 3.90  Granted 1,290,000 3.40  Exercised - -  Expired (500,000) 3.50  Balance outstanding at March 31, 2016 2,002,718 $ 3.50  Balance exercisable at March 31, 2016 2,002,718 $ 3.50   On September 9, 2014, we offered the holders of 367,647 warrants the right to exercise all of those warrants, for an aggregate of 367,647 shares of our common stock, based on the terms of an early exercise offer wherein such warrants became exercisable at a reduced exercise price of $4.00 per share and new warrants would be issued to such investors, so long as the exercise thereof occurred on or before September 10, 2014. All purchasers acted on the early exercise offer and we issued 367,647 shares of our common stock for net proceeds to us of $ 1,470,589 . We determined that the modification of the exercise price of the warrants from $4.20 per share to $4.00 per share should be recorded as a cost to induce the exercise of the warrants. As such, we recognized the difference of $21,218 between the fair value of the warrants before and after the modification as a cost in the accompanying statements of operations for the year ended March 31, 2015. In conjunction with the early exercise offer, we issued to the warrant holders who acted on such offer new, replacement warrants to purchase an additional 367,647 shares of our common stock. The terms and conditions of the replacement warrants are the same as the terms of the originally issued warrants, except that: (a) the initial exercise date is September 10, 2014 rather than June 28, 2013; (b) the replacement warrants have an exercise term of five years rather than nine months; (c) the exercise price of the replacement warrants is $4.50 per share (subject to anti-dilution and other adjustments as described below and a floor exercise price of $2.00 per share); and (d) the replacement warrants and the shares of common stock underlying such warrants are not registered under the Securities Act and are restricted securities. The new warrants are exercisable immediately upon issuance. These replacement warrants also provide for the adjustment of the exercise price and/or number of shares issuable upon exercise thereof in connection with stock dividends and splits, subsequent rights offerings, pro rata distributions to the Company’s common stockholders and subsequent equity sales by the Company at an effective price lower than the then-current exercise price of the replacement warrants. We determined that the fair value of these replacement warrants at their issue date of $940,549 was recorded as a cost to induce the exercise of the originally issued nine-month warrants in the accompanying statements of operations for the year ended March 31, 2015. In May 2015, the Company granted 500,000 Series A warrants, 500,000 Series B warrants and 250,000 Series C warrants in connection with an offering of the Company’s common stock for cash. Each Series A Warrant has an exercise price of $4.50 per share, was immediately exercisable, and expires on the five year anniversary of the date of issuance. Each Series B Warrant has an exercise price of $3.50 per share, was immediately exercisable, and expire d on the nine month anniversary of the date of issuance. Each Series C Warrant has an exercise price of $4.00 per share, was immediately exercisable, and will expire on the one year anniversary of the date of issuance. T he Company also issued Placement Agent Warrants to purchase up to 40,000 shares of the Company’s common stock to H.C. Wainwright. The Placement Agent Warrants have an exercise price of $3.75 per share, a term of 5 years, and are exercisable immediately.  The exercise price of the Series A Warrants granted to the purchasers of the Offering includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants, provided that the exercise price shall not be reduced to less than $2.00 per share. Additionally, all of the Warrants granted to the purchasers of the Offering and to the placement agent are subject to provision for certain fundamental transactions. In consideration of applicable guidance, the Company has determined that none of the warrants are considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterizes the fair value of these warrants as derivative liabilities (See Note 3).  In consideration of applicable guidance, the Company has determined that the warrants are not considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterized the fair value of these warrants of $401,127 as a derivative liability upon issuance (See Note 4).  Warrants issued to employees On August 25, 2014, we entered into employment agreements with two new employees, pursuant to which, these employees became entitled to receive warrants to purchase an aggregate of 440,000 shares of the Company’s common stock. These warrants have an exercise price of $3.00 , and a term of ten years from issue date. Vesting terms of these warrants are as follows: (i) warrants to purchase 80,000 shares of common stock vested immediately at their grant date , (ii) warrants to purchase 200,000 shares of common stock have vesting terms ranging from one year to three years, and (iii) warrants to purchase 160,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement (See Note 9) . During the years ended March 31, 2016 and 2015, we expensed total stock-based compensation related to the vesting of these warrants of $182,072 and $432,772 , respectively and the remaining unamortized cost of the outstanding warrants at March 31, 2016 was $91,036 . The aggregate intrinsic value of all of the outstanding and exercisable w arrants at March 31, 201 6 was $0 .

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2016
INCOME TAXES [Abstract]
INCOME TAXES	8. INCOME TAXES The Company has no tax provision for any period presented due to our history of operating losses. As of March 31, 2016, the Company had net operating loss ca rry forwards of approximately $8,900,000 that may be available to reduce future years' taxable income through 2030. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as management has determined that their realization is not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.  The Company adopted accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under these rules, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. These accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of March 31, 201 6 no liability for unrecognized tax benefits was required to be recorded.

DISTRIBUTION AND LICENSE AGREEM

DISTRIBUTION AND LICENSE AGREEMENTS	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
DISTRIBUTION AND LICENSE AGREEMENTS [Abstract]
DISTRIBUTION AND LICENSE AGREEMENTS	8. DISTRIBUTION AND LICENSE AGREEMENTS Related to our legacy stevia business products and technologies, on August 25, 2014, we entered into a distribution agreement where Qualipride International (“Qualipride”) agreed to provide stevia products to the Company at its cost, plus up to 2% for handling costs and up to a 5% sales commission. The Company will account for such costs as such sales are made, or as such other direct costs are incurred. During the year ended March 31, 2016, neither any sales were made nor were other direct costs incurred pursuant to the terms of the distribution agreement. Concurrently, we also entered into a technology license agreement with Qualipride, Mr. Dong Yuejin and Mr. Guo Yuxiao in which we obtained an exclusive license outside China to use Qualipride’s proprietary methods and designs for stevia extraction and purification facilities. The Company will account for the potential costs of such license and obligation once adequate financing has been received to finance facility construction contemplated within the agreement, if such financing occurs. During the three months ended June 30, 2016, the Company did not receive any financing pursuant to the terms of the license agreement. Under employment agreements related to the distribution and license agreements, Mr. Dong and Mr. Guo are entitled to receive an aggregate of 240,000 restricted shares of our common stock (see Note 5) and warrants to purchase up to an aggregate of 440,000 shares of our common stock (see Note 7). An aggregate of 40,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 80,000 shares of our common stock vested immediately upon issuance. An aggregate of 100,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 200,000 shares of our common stock have vesting terms ranging from one to three years. An aggregate of 100,000 shares of our restricted common stock will be issued and warrants to purchase up to an aggregate of 160,000 shares of our common stock will vest once we achieve certain financial and operational milestones. The Company will account for the costs of the 100,000 shares of common stock and warrants to purchase up to an aggregate of 160,000 shares of common stock, at the time their issuance becomes probable. The distribution, license and employment agreements are all scheduled to terminate in August 2016, and the Company does not intend to renew or restructure them unless it obtains significant new strategic partnering interest or supply contracts from multinational ingredient or beverage companies related to its stevia products or technologies .	9. DISTRIBUTION AND LICENSE AGREEMENTS  Related to our legacy stevia business products and technologies, on August 25, 2014, we entered into a distribution agreement where Qualipride International (“Qualipride”) agreed to provide stevia products to the Company at its cost, plus up to 2% for handling costs and up to a 5% sales commission. The Company will account for such costs as such sales are made, or as such other direct costs are incurred. During the year ended March 31, 2016, neither any sales were made nor were other direct costs incurred pursuant to the terms of the distribution agreement. Concurrently, we also entered into a technology license agreement with Qualipride, Mr. Dong Yuejin and Mr. Guo Yuxiao in which we obtained an exclusive license outside China to use Qualipride’s proprietary methods and designs for stevia extraction and purification facilities. The Company will account for the potential costs of such license and obligation once adequate financing has been received to finance facility construction contemplated within the agreement, if such financing occurs. During the year ended March 31, 2016, the Company did not receive any financing pursuant to the terms of the license agreement. Under employment agreements related to the distribution and license agreements, Mr. Dong and Mr. Guo are entitled to receive an aggregate of 240,000 restricted shares of our common stock (see Note 5) and warrants to purchase up to an aggregate of 440,000 shares of our common stock (see Note 7). An aggregate of 40,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 80,000 shares of our common stock vested immediately upon issuance . An aggregate of 100,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 200,000 shares of our common stock have vesting terms ranging from one to three years. An aggregate of 100,000 shares of our restricted common stock will be issued and warrants to purchase up to an aggregate of 160,000 shares of our common stock will vest once we achieve certain financial and operational milestones . The Company will account for the costs of the 100,000 shares of common stock and warrants to purchase up to an aggregate of 160,000 shares of common stock, at the time their issuance becomes probable. During the year ended March 31, 2016, no such milestones were met and as of the year ended March 31, 2016, we owed no compensation pursuant to these employment agreements.  The distribution, license and employment agreements are all scheduled to terminate in August 2016, and the Company does not intend to renew or restructure them unless it obtains significant new strategic partnering interest or supply contracts from multinational ingredient or beverage companies related to its stevia products or technologies.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS [Abstract]
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	7. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS Related party lease obligations On April 23, 2012, the Company entered into a lease agreement (the “Carlson Lease”) with One World Ranches, LLC (“One World Ranches”), which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California. The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease.  Aggregate payments under the above lease for the three months ended June 30, 2016 and 2015 were $0 and $10,900 , respectively.	10. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS Related party lease obligations On April 23, 2012, the Company entered into a lease agreement with One World Ranches LLC (“One World Ranches”), pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California (the “Carlson Lease”). The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease. On August 18, 2012, the Company entered into a lease agreement (the “Sacramento Lease”) with Sacramento Valley Real Estate, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company leases an apartment located at 33-800 Clark Avenue, Yuba City, California. This Company used this apartment as an alternative to renting hotel rooms for management use since several of our managers are not resident in Yuba City. The month to month lease began on August 20, 2012 and was terminated in June 2015. The Company’s rent payment was $1,000 per month. On August 22, 2012, the Company paid $1,000 as a refundable security deposit under the Sacramento lease. Aggregate payments under the above leases for the years ended March 31, 2016 and 2015 were $30,600 and $49,000 , respectively.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Mar. 31, 2016
COMMITMENTS [Abstract]
COMMITMENTS	11. COMMITMENTS Related to our legacy stevia products and technologies, in addition to intellectual property developed internally, we previously licensed exclusive and worldwide rights to certain patents and patent applications related to microbial production of steviol and steviol glycosides from Vineland Research and Innovations Centre, Inc. entered into in August 2012, amended in October 2013 (the “Vineland License”), and terminated in May 2016. Pursuant to the Vineland License, we agreed to total cash fees due and payable within the first year of the agreement of $50,000 , all of which have been paid and recorded as expenses.Under the Vineland License we will owe royalties of 0.5% of the sale price of products developed using the intellectual property, and in the third year and all subsequent years of the Vineland License the Company will owe a minimum annual royalty of $10,000 . No additional payments will be owed under the Vineland License as it was terminated in May 2016.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS  In July 2016, we issued options to purchase 1,525,703 shares of our common stock to six employees and one director with a fair value of $365,330 which will be amortized over 24 months as the options vest. The fair value of these options granted was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34%, (ii) discount rate of 1.60 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. These options have an exercise price of $0.50 per share and expire ten years from the date of issuance.  In July 2016, we issued options to purchase 185,118 shares of our common stock to two consultants with a fair value of $44,326 at grant date. These options have an exercise price of $0.50 per share and expire ten years from the date of issuance. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34%, (ii) discount rate of 1.60 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The fair value of the option grants to the consultants will be recalculated each quarter and will be amortized over 24 months as the options vest based on their fair value at the end of each quarterly reporting period.  In July 2016, we issued 1,436,170 shares of restricted common stock to our Chief Executive Officer and the Chairman of our board of directors with a fair value of $718,085, which will be amortized over 20 months as the shares vest.	12. SUBSEQUENT EVENTS  In May 201 6 , the Company entered into a securities purchase agreement with the purchasers identified therein providing for the issuance and sale by the Company to the p urchasers, in a private placement, of an aggregate of 2,650,000 shares of the Company’s common stock (collectively, the “Shares”) and Warrants to purchase up to an aggregate of 7,950,000 shares of the Company’s common stock ,( the “Warrants”, and the shares issuable upon exercise of the Warrants, collectively, the “Warrant Shares”), at a price of $0.10 per Share (the “Offering”). The Warrants have an exercise price of $0.17 per share and expire six months from the date of issuance. The Offering closed on May 4 , 201 6 . T he aggregate proceeds to the Company from the sale of the Shares and Warrants was approximately $265,000 .  I n May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchang e of one (1) share of the Company’s c ommon s tock for each 10 shares of c ommon s tock outstanding or exercisable under any outstanding warrants or option agreements and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000 . These corporate changes became effective on July 20, 2016 and are reflected in these financial statements.  In July 2016, we issued options to purchase 1,525,703 shares of our common stock to six employees and one director with a fair value of $365,330 which will be amortized over 24 months as the options vest. The fair value of these options granted was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34% , (ii) discount rate of 1.60 % , (iii) zero expected dividend yield, and (iv) expected life of 5 years. These options have an exercise price of $0.50 per share and expire ten years from the date of issuance.  In July 2016, we issued options to purchase 185,118 shares of our common stock to two consultants with a fair value of $44,326 at grant date. These options have an exercise price of $0.50 per share and expire ten years from the date of issuance. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34 %, (ii) discount rate of 1.60 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The fair value of the option grants to the consultants will be recalculated each quarter and will be amortized over 24 months as the options vest based on their fair value at the end of each quarterly reporting period.  In July 2016, we issued 1,436,170 shares of restricted common stock to our Chief Executive Officer and the Chairman of our board of directors with a fair value of $718,015 , which will be amortized over 20 months as the shares vest.

BUSINESS AND BASIS OF OPERATI20

BUSINESS AND BASIS OF OPERATIONS (Policy)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
BUSINESS AND BASIS OF OPERATIONS [Abstract]
Going Concern	Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and utilized cash in operations since inception resulting in stockholders’ deficit of $513,343 as of June 30, 2016, and further losses are anticipated in the development of its business. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2016 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the business for the 6 months after June 30, 2016. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations . We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.	Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and has a stockholders’ deficiency of $518,165 as at March 31, 2016, and further losses are anticipated in the development of its business. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate as of March 31, 2016 we will have sufficient funds to operate the business for the next 6 months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, seeking to license or acquire new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. Subsequent to March 31, 2016, we completed a private placement of our common stock and warrants resulting in net proceeds of $265,000 , of which proceeds amounting to $99,970 were received in March 2016. We do not have any other firm commitments for future capital. Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, significant revenue to fund our business from our operations, and will need to obtain most of our necessary funding from external sources in the near term. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property and could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of our outstanding derivative liabilities.	Use of Estimates and Assumptions The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and input assumptions used in the valuation of derivative liabilities.
Revenues		Revenues Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for products and/or services that have been delivered in the normal course of business, title has passed, the selling price is both fixed and determinable, and collectability is reasonably assured, all of which generally occurs upon shipment of the Company’s product or delivery of the product to the destination specified by the customer. The Company determines whether delivery has occurred based on when title transfers and the risks and rewards of ownership have transferred to the buyer, which usually occurs when the Company ships the products. The Company regularly reviews its customers’ financial positions to ensure that collectability is reasonably assured. Except for warranties, the Company has no post-sales obligations.
Accounts Receivable	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At June 30, 2016, and March 31, 2016, the allowance for doubtful accounts and returns and discounts was approximately $17,500 .	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At March 31, 2016 and 2015, the allowance for doubtful accounts and returns and discounts was approximately $17,500 and $2,500 , respectively.
Financial Assets and Liabilities Measured at Fair Value	Financial Assets and Liabilities Measured at Fair Value The Company accounts for the fair value of financial instruments in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) topic 820, “Fair Value Measurements and Disclosures” (ASC 820), formerly SFAS No. 157 “Fair Value Measurements”. ASC 820 defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts payable and accrued liabilities, each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The Company uses Level 2 inputs for its valuation methodology for the warrant derivative liabilities as their fair values were determined by using a probability weighted average Black-Scholes-Merton pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. At June 30, 2016 and March 31, 2016, the Company’s balance sheet includes the fair value of derivative liabilities that were measured using level 2 measurements. The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC 815.	Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:  Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The fair value of the derivative liabilities of $401,127 and $1,406,596 at March 31, 2016 and 2015, respectively, were valued using Level 2 inputs.  The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2016 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2016, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.	Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB ASC, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.	Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share  The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period.  As of June 30, 2016 potentially dilutive securities include options to acquire 892,500 shares of common stock and warrants to acquire 9,702,713 shares of common stock. At June 30, 2015 potentially dilutive securities include options to acquire 830,000 shares of common stock and warrants to acquire 2,502,704 shares of common stock. The basic and fully diluted shares for the three months ended June 30, 2016 are the same because the inclusion of the potential shares would have had an anti-dilutive effect. Diluted net income per common share for the three months ended June 30, 2015 was calculated based on an increased number of shares that would be outstanding as follows:      Three Months Ended June 30,  2016 2015  Numerator:  Net income (loss) $ (439,405) $ 215,594  Denominator:  Weighted average shares outstanding (basic) 10,069,358 7,568,760  Effect of dilutive stock options - 210,000  Weighted average shares outstanding (diluted) 10,069,358 7,778,760  Net income (loss) per share  Basic $ (0.04) $ 0.03  Diluted $ (0.04) $ 0.03  	Basic and Diluted Loss Per Share The Company computes loss per share in accordance with ASC Topic 260, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:      March 31,  2016 2015  Options 909,167 632,500  Warrants 2,002,713 1,212,713  Total 2,911,880 1,845,213 
Research and Development		Research and Development  Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers . ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.  In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases . ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements	Recent Accounting Pronouncements  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers . ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.  In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  In November 2014, the FASB issued Accounting Standards Update No. 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in ASU 2014-6 do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. ASU 2014-6 applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.  In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases . ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share		The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:      March 31,  2016 2015  Options 909,167 632,500  Warrants 2,002,713 1,212,713  Total 2,911,880 1,845,213 
Schedule of Earnings (Loss) Per Share	Diluted net income per common share for the three months ended June 30, 2015 was calculated based on an increased number of shares that would be outstanding as follows:      Three Months Ended June 30,  2016 2015  Numerator:  Net income (loss) $ (439,405) $ 215,594  Denominator:  Weighted average shares outstanding (basic) 10,069,358 7,568,760  Effect of dilutive stock options - 210,000  Weighted average shares outstanding (diluted) 10,069,358 7,778,760  Net income (loss) per share  Basic $ (0.04) $ 0.03  Diluted $ (0.04) $ 0.03 

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
DERIVATIVE LIABILITY [Abstract]
Valuation Assumptions for Derivative Liabilities	As of March 31, 2016 and June 30, 2016, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Warrants:     June 30, 2016 March 31, 2016 Exercise Price $ 2.00 - 4.25 $ 3.00 - 4.50  Stock Price $ 0.50 $ 0.70 Risk-free interest rate 0.48 - 0.86 % 0.19 - 1.04 %  Expected volatility 126.31 % 105.06 - 124.77 % Expected life (in years) 1.25 - 3.9 years 0.1 - 4.2 years  Expected dividend yield 0 0   Fair Value: $ 335,802 $ 401,127  	At the applicable dates of issuance and as of March 31, 201 5 and March 31, 201 6 , the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:     Date of Modification September 24, 2014 March 31, 2015 Upon Issuance May 11, 2015 March 31, 2016 Exercise Price $ 4.00 – 4.50 $ 3.40 - 4.50 $ 3.50 - 4.50 $ 3.00 – 4.50  Stock Price $ 4.20 $ 3.80 $ 2.90 $ 0.70 Risk-free interest rate 1.78 - 2.0 % 0.41 - 1.25 % 0.17 - 1.59 % 0.19 – 1.04 %  Expected volatility 84.45 % 76.26 % 76.26 - 107.5 % 105.06 - 124.77 % Expected life (in years) 0.01 – 5.0 years 2.50 - 4.5 years 0.75 – 5.0 years 0.1 – 4.2 years  Expected dividend yield 0.00 0.00 0.00 0.00   Fair Value: $ 961,767 $ 1,406,596 $ 1,694,651 $ 401,127 

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Jun. 30, 2016
STOCKHOLDERS' DEFICIENCY [Abstract]
Schedule of Nonvested Restricted Stock Unit Activity	The following table summarizes restricted common stock activity:     Number of Shares  Non-vested shares, March 31, 2016 175,833  Granted -  Vested (2,500)  Forfeited -  Non-vested shares, June 30, 2016 173,333 

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
STOCK OPTIONS [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity for the three months ended June 30, 2016 is presented below:     Shares Weighted Average Exercise Price  Balance at March 31, 2016 907,500 $ 3.30  Granted - -  Exercised - -  Cancelled (15,000) 3.40  Balance outstanding at June 30, 2016 892,500 $ 2.86  Balance exercisable at June 30,2016 717,501 $ 2.99 	A summary of the Company’s stock option activity during the fiscal years ended March 31, 2015 and 2016 is as follows:      Shares Weighted Average Exercise Price  Balance at March 31, 2014 515,000 $ 2.60  Granted 135,000  Exercised (5,000)  Cancelled (12,500)  Balance outstanding at March 31, 2015 632,500 $ 3.30  Granted 275,000  Exercised -  Cancelled -  Balance outstanding at March 31, 2016 907,500 $ 3.30  Balance exercisable at March 31,2016 679,376 $ 3.20 
Options to Purchase Common Shares	At June 30, 2016, options to purchase common shares were outstanding as follows:     Number of options Weighted Average Exercise Price Weighted Average Grant-date Stock Price   Options Outstanding, June 30, 2016 130,000 $ 1.00 $ 10.00  10,000 $ 1.50 $ 0.40  287,500 $ 2.00 - 2.70 $ 2.00 - 2.70  205,000 $ 3.10 - 3.80 $ 3.10 - 3.80  200,000 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  892,500   Options Exercisable, June 30,2016 130,000 $ 1.00 $ 10.00  2,500 $ 1.50 $ 0.40  157,500 $ 2.00 - 2.70 $ 2.00 - 2.70  171,668 $ 3.10 - 3.80 $ 3.10 - 3.80  195,833 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  717,501 	A summary of the Company’s stock options outstanding as of March 31, 2016 is as follows:    Number of Options Weighted Average Exercise Price Weighted Average Grant-date Stock Price  Options Outstanding, March 31, 2016 130,000 $ 1.00 $ 10.00  10,000 1.50 1.50  287,500 $ 2.00 - 2.70 $ 2.00 - 2.70  220,000 $ 3.10 - 3.80 $ 3.10 - 3.80  199,167 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  907,500  Options Exercisable, March 31, 2016 130,000 $ 1.00 $ 10.00  123,750 $ 2.00 - 2.70 $ 2.00 - 2.70  171,667 $ 3.10 - 3.80 $ 3.10 - 3.80  193,959 $ 4.00 - 4.70 $ 4.00 - 4.70  60,000 $ 5.10 $ 5.10  679,376 

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
WARRANTS [Abstract]
Summary of Warrant Activity	At June 30, 2016, warrants to purchase common shares were outstanding as follows:     Shares Weighted Average Exercise Price  Balance at March 31, 2016 2,002,718 $ 3.50  Granted 7,950,000 0.17  Exercised - -  Expired (250,000) $ 4.00  Balance outstanding and exercisable at June 30, 2016 9,702,718 $ 0.55 	A summary of warrants to purchase common stock issued during the fiscal years ended March 31, 2015 and 2016 is as follows:      Shares Weighted Average Exercise Price  Balance outstanding at March 31, 2014 772,717 $ 4.10  Granted 807,648 3.70  Exercised (367,647) 4.00  Cancelled - -  Balance outstanding at March 31, 2015 1,212,718 $ 3.90  Granted 1,290,000 3.40  Exercised - -  Expired (500,000) 3.50  Balance outstanding at March 31, 2016 2,002,718 $ 3.50  Balance exercisable at March 31, 2016 2,002,718 $ 3.50 

BUSINESS AND BASIS OF OPERATI27

BUSINESS AND BASIS OF OPERATIONS (Details)	Oct. 11, 2011$ / sharesshares	May 31, 2016USD ($)	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)	Oct. 09, 2011$ / sharesshares
Stock split description				In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company's common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements
Common stock, shares authorized | shares	525,000,000		1,000,000,000	1,000,000,000	1,000,000,000	1,000,000,000		75,000,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001		$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Common stock, shares issued | shares	51,450,000		7,911,708	7,911,708	10,561,708	7,296,892		7,350,000
Common stock, shares outstanding | shares	51,450,000		7,911,708	7,911,708	10,561,708	7,296,892		7,350,000
Stockholders' equity (deficiency) | $			$ (518,165)	$ (518,165)	$ (513,343)	$ (1,079,300)	$ (110,376)
Proceeds from issuance of private placement | $			$ 99,970
Common Stock [Member]
Stock split description				on October 10, 2011, we effected a seven for one forward stock split of authorized, issued and outstanding common stock. As a result, our authorized capital was increased from 75,000,000 shares of common stock with a par value of $0.001 to 525,000,000 shares of common stock with a par value of $0.001, and issued and outstanding shares increased from 7,350,000 to 51,450,000.
Stock split, conversion ratio	7
Subsequent Event [Member]
Stock split, conversion ratio		10
Proceeds from issuance of private placement | $		$ 265,000

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	May 11, 2015	Sep. 24, 2014
Allowance for doubtful accounts receivable	$ 17,500		$ 17,500	$ 2,500
Antidilutive securities excluded from computation of earnings per share			2,911,880	1,845,213
Derivative liability	$ 335,802		$ 401,127	$ 1,406,596	$ 1,694,651	$ 961,767
Equity Option [Member]
Antidilutive securities excluded from computation of earnings per share	892,500	830,000
Warrant [Member]
Antidilutive securities excluded from computation of earnings per share	9,702,713	2,502,704	2,002,713	1,212,713

SUMMARY OF SIGNIFICANT ACCOUN29

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Antidilutive Securities Excluded from Earnings per Share) (Details) - shares	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			2,911,880	1,845,213
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			909,167	632,500
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	9,702,713	2,502,704	2,002,713	1,212,713

SUMMARY OF SIGNIFICANT ACCOUN30

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Calculation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Net income (loss)	$ (439,405)	$ 215,594	$ (141,325)	$ (4,048,373)
Weighted average number of common shares outstanding, basic	10,069,358	7,568,760
Effect of dilutive stock options		210,000
Weighted average number of common shares outstanding - diluted	10,069,358	7,778,760
Net income (loss) per common share - basic	$ (0.04)	$ 0.03
Net income (loss) per common share - diluted	$ (0.04)	$ 0.03

ACQUISITION FROM RELATED PARTY

ACQUISITION FROM RELATED PARTY (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2014	Mar. 31, 2016	Jun. 30, 2016	Mar. 31, 2015
Accounts payable and accrued liabilities		$ 244,937	$ 232,953	$ 134,007
Percipio Biosciences Inc [Member]
Purchase of assets from related party	$ 50,000
Accounts payable and accrued liabilities		11,950
Senior scientist annual salary		$ 95,000
Percipio Biosciences Inc [Member] | Chief Executive Officer [Member]
Ownership percentage in acquired party held by an officer of the reporting entity	20.00%

DERIVATIVE LIABILITY (Narrative

DERIVATIVE LIABILITY (Narrative) (Details) - USD ($)	Sep. 10, 2014	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	May 31, 2015	May 11, 2015	Sep. 24, 2014
DERIVATIVE LIABILITY [Abstract]
Warrants valuation method				Black-Scholes-Merton pricing model
Derivative liability		$ 335,802		$ 401,127	$ 1,406,596		$ 1,694,651	$ 961,767
Cost to induce exercise of warrants	$ 21,218				(961,767)
Change in fair value of derivative liability		(14,953)	$ 1,113,801	2,600,809	724,617
Fair value of warrants accounted for as derivatives	$ 940,549
Extinguishment of derivative liability		80,278		$ 99,311	$ 269,368
Value of warrants issued, derivative liability						$ 1,694,651
Increase (decrease) in derivative liabilities		$ 14,953

DERIVATIVE LIABILITY (Valuation

DERIVATIVE LIABILITY (Valuation of Derivative Liabilities) (Details) - USD ($)	May 11, 2015	Sep. 24, 2014	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Price	$ 2.90	$ 4.20	$ 0.50	$ 0.70	$ 3.80
Risk-free interest rate				1.04%
Expected volatility		84.45%	126.31%		76.26%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%
Fair Value of Derivative Liability	$ 1,694,651	$ 961,767	$ 335,802	$ 401,127	$ 1,406,596
Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	$ 4.50	$ 4.50	$ 4.25	$ 4.50	$ 4.50
Risk-free interest rate	1.59%	2.00%	0.86%		1.25%
Expected volatility	107.50%			124.77%
Expected life (in years)	5 years	5 years	3 years 10 months 24 days	4 years 2 months 12 days	4 years 6 months
Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	$ 3.50	$ 4	$ 2	$ 3	$ 3.40
Risk-free interest rate	0.17%	1.78%	0.48%	0.19%	0.41%
Expected volatility	76.26%			105.06%
Expected life (in years)	9 months	4 days	1 year 3 months	4 days	2 years 6 months

STOCKHOLDERS' DEFICIENCY (Equit

STOCKHOLDERS' DEFICIENCY (Equity Financing) (Details)	Sep. 10, 2014USD ($)	May 31, 2016USD ($)$ / sharesshares	May 31, 2015USD ($)$ / shares$ / securityshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)	Mar. 31, 2016USD ($)$ / shares$ / securityshares	Mar. 31, 2015USD ($)$ / shares	Mar. 31, 2014$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement | shares		999,700
Shares issued, value		$ 99,970		$ 165,030
Proceeds from sale of common stock and warrants, net				$ 165,030	$ 1,291,574	$ 1,291,574
Fair value of warrants accounted for as derivatives	$ 940,549
Exercise price of warrants | $ / shares				$ 0.55		$ 3.50	$ 3.90	$ 4.10
Value of warrants issued, derivative liability			$ 1,694,651
Adjustments to additional paid in capital, warrants issued				$ 35,014		$ 182,072	$ 432,772
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement | shares				2,650,000		500,000
Shares issued, value				$ 2,650		$ 500
Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants | shares			40,000
Exercise price of warrants | $ / shares			$ 3.75
Exercise term of warrants issued			5 years
Securities Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement | shares		2,650,000	500,000
Number of shares called by exercise of warrants | shares		7,950,000	1,250,001
Proceeds from sale of common stock and warrants, gross			$ 1,500,000
Shares issued, price per share | $ / shares		$ 0.10	$ 3
Payments of stock issuance costs			$ 208,426
Proceeds from sale of common stock and warrants, net		$ 265,000	1,291,574
Exercise price of warrants | $ / shares		$ 0.17
Exercise term of warrants issued		6 months
Value of warrants issued, derivative liability			1,694,651
Adjustments to additional paid in capital, warrants issued			$ 408,077
Securities Purchase Agreement Warrants, Series A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants | shares			500,000
Exercise price of warrants | $ / shares			$ 4.50
Exercise term of warrants issued			5 years
Minumum exercise price for automatic reset provision | $ / security			2			2
Securities Purchase Agreement Warrants, Series B [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants | shares			500,000
Exercise price of warrants | $ / shares			$ 3.50
Exercise term of warrants issued			9 months
Securities Purchase Agreement Warrants, Series C [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants | shares			250,000
Exercise price of warrants | $ / shares			$ 4
Exercise term of warrants issued			1 year

STOCKHOLDERS' DEFICIENCY (Commo

STOCKHOLDERS' DEFICIENCY (Common Stock Issued to Employees for Services with Vesting Terms) (Details) - USD ($)	3 Months Ended		12 Months Ended				36 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees				140,000
Fair value of shares issued to employees	$ 683,000			$ 420,000			$ 683,000
Shares vested (value)	24,000	$ 59,234	$ 161,936	$ 329,511
Stock-based compensation expense not yet recognized	$ 43,000		86,000				$ 86,000
Unvested Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reclassication of unvested, issued common stock to paid-in capital			$ 149,714
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees			100,000
Vesting 16 to 60 Months [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees						70,000
Fair value of shares issued to employees						$ 189,000
Vesting 31 Months [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted					31 months
Shares issued to employees					10,000
Fair value of shares issued to employees					$ 36,000
​Vesting 24 Months [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				24 months
Shares issued to employees				10,000
Fair value of shares issued to employees				$ 38,000
​Vesting 12 to 36 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees				100,000
​Vesting Immediately [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees				40,000
Minimum [Member] | Vesting 16 to 60 Months [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted						16 months
Minimum [Member] | ​Vesting 12 to 36 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				12 months
Maximum [Member] | Vesting 16 to 60 Months [Member] | 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted						60 months
Maximum [Member] | ​Vesting 12 to 36 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				36 months

STOCKHOLDERS' DEFICIENCY (Com36

STOCKHOLDERS' DEFICIENCY (Common Stock Issued to Consultants for Services) (Details) - USD ($)	1 Months Ended				2 Months Ended	12 Months Ended
	Jul. 31, 2015	May 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Nov. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares	31,000	32,500			51,316
Common stock issued for services, value	$ 61,000	$ 115,000			$ 100,000	$ 276,000	$ 338,900
Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares							79,098
Common stock issued for services, value							$ 294,100
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares			4,000	7,895
Common stock issued for services, value			$ 14,800	$ 30,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares						114,816	90,992
Common stock issued for services, value						$ 115	$ 91

EQUITY (Schedule of Non-Vested

EQUITY (Schedule of Non-Vested Restricted Common Stock Activity) (Details) - Restricted Stock [Member]	3 Months Ended
	Jun. 30, 2016shares
Non-vested shares, March 31, 2016	175,833
Granted
Vested	(2,500)
Forfeited
Non-vested shares, June 30, 2016	173,333

STOCK OPTIONS (Narrative) (Deta

STOCK OPTIONS (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercised during period (shares)					5,000
Proceeds from exercise of options					$ 5,000
Stock-based compensation, options vested (value)		$ 39,905	$ 119,764	$ 286,248	$ 233,310
Unamortized cost of outstanding stock-based awards		$ 263,460		$ 345,000
Weighted average remaining vesting period		2 years		2 years
Options outstanding, intrinsic value		$ 0	130,000	$ 0
Intrinsic value of stock options outstanding and exercisable		$ 0	$ 130,000
Options granted				275,000	135,000
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period (shares)				137,500	112,500
Expiration period of options granted				10 years	10 years
Expected volatility rate of options granted				76.26%	81.84%
Expected discount rate of options granted				2.19%	1.62%
Expected dividend yield of options granted				0.00%	0.00%
Expected life of options granted				5 years	5 years
Grant-date fair value of options granted				$ 233,000	$ 300,000
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period (shares)				140,000	22,500
Expected volatility rate of options granted					76.26%
Expected discount rate of options granted				2.17%	2.17%
Expected dividend yield of options granted				0.00%	0.00%
Expected life of options granted				5 years	5 years
Grant-date fair value of options granted				$ 131,000	$ 88,000
Options exercised during period (shares)	5,000
Options exercised during period, exercise price	$ 1
Proceeds from exercise of options	$ 5,000
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted				0 months	0 months
Minimum [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted				3 years	5 years
Vesting period of options or warrants granted				0 months	0 months
Expected volatility rate of options granted (minimum)				76.26%
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options or warrants granted				36 months	36 months
Maximum [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted				10 years	10 years
Vesting period of options or warrants granted				36 months	36 months
Expected volatility rate of options granted (maximum)				107.51%

STOCK OPTIONS (Schedule of Stoc

STOCK OPTIONS (Schedule of Stock Option Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
STOCK OPTIONS [Abstract]
Shares, beginning balance outstanding	907,500	632,500	515,000
Shares, Granted		275,000	135,000
Shares, Exercised			(5,000)
Shares, Cancelled	(15,000)		(12,500)
Shares, ending balance outstanding	892,500	907,500	632,500
Shares, Balance exercisable	717,501	679,376
Weighted Average Exercise Price, beginning balance outstanding	$ 3.30	$ 3.30	$ 2.60
Weighted Average Exercise Price, Cancelled	3.40
Weighted Average Exercise Price, ending balance outstanding	2.86	3.30	$ 3.30
Weighted Average Exercise Price, Balance exercisable	$ 2.99	$ 3.20

STOCK OPTIONS (Summary of Stock

STOCK OPTIONS (Summary of Stock Options Outstanding) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	892,500	907,500	632,500	515,000
Weighted Average Exercise Price, Options Outstanding	$ 2.86	$ 3.30	$ 3.30	$ 2.60
Number of Options Exercisable	717,501	679,376
Weighted Average Exercise Price, Options Exercisable	$ 2.99	$ 3.20
Stock Options 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	130,000	130,000
Weighted Average Exercise Price, Options Outstanding	$ 1	$ 1
Weighted Average Grant-Date Stock Price, Options Outstanding	$ 10	$ 10
Number of Options Exercisable	130,000	130,000
Weighted Average Exercise Price, Options Exercisable	$ 1	$ 1
Weighted Average Grant-Date Stock Price, Options Exercisable	$ 10	$ 10
Stock Options 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	10,000	10,000
Weighted Average Exercise Price, Options Outstanding	$ 1.50	$ 1.50
Weighted Average Grant-Date Stock Price, Options Outstanding	$ 0.40	$ 1.50
Number of Options Exercisable	2,500
Weighted Average Exercise Price, Options Exercisable	$ 1.50
Weighted Average Grant-Date Stock Price, Options Exercisable	$ 0.40
Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	287,500	287,500
Number of Options Exercisable	157,500	123,750
Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	205,000	220,000
Number of Options Exercisable	171,668	171,667
Stock Options 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	200,000	199,167
Number of Options Exercisable	195,833	193,959
Stock Options 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	60,000	60,000
Weighted Average Exercise Price, Options Outstanding	$ 5.10	$ 5.10
Weighted Average Grant-Date Stock Price, Options Outstanding	$ 5.10	$ 5.10
Number of Options Exercisable	60,000	60,000
Weighted Average Exercise Price, Options Exercisable	$ 5.10	$ 5.10
Weighted Average Grant-Date Stock Price, Options Exercisable	5.10	5.10
Minimum [Member] | Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	2	2
Weighted Average Grant-Date Stock Price, Options Outstanding	2	2
Weighted Average Exercise Price, Options Exercisable	2	2
Weighted Average Grant-Date Stock Price, Options Exercisable	2	2
Minimum [Member] | Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	3.10	3.10
Weighted Average Grant-Date Stock Price, Options Outstanding	3.10	3.10
Weighted Average Exercise Price, Options Exercisable	3.10	3.10
Weighted Average Grant-Date Stock Price, Options Exercisable	3.10	3.10
Minimum [Member] | Stock Options 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	4	4
Weighted Average Grant-Date Stock Price, Options Outstanding	4	4
Weighted Average Exercise Price, Options Exercisable	4	4
Weighted Average Grant-Date Stock Price, Options Exercisable	4	4
Maximum [Member] | Stock Options 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	2.70	2.70
Weighted Average Grant-Date Stock Price, Options Outstanding	2.70	2.70
Weighted Average Exercise Price, Options Exercisable	2.70	2.70
Weighted Average Grant-Date Stock Price, Options Exercisable	2.70	2.70
Maximum [Member] | Stock Options 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	3.80	3.80
Weighted Average Grant-Date Stock Price, Options Outstanding	3.80	3.80
Weighted Average Exercise Price, Options Exercisable	3.80	3.80
Weighted Average Grant-Date Stock Price, Options Exercisable	3.80	3.80
Maximum [Member] | Stock Options 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	4.70	4.70
Weighted Average Grant-Date Stock Price, Options Outstanding	4.70	4.70
Weighted Average Exercise Price, Options Exercisable	4.70	4.70
Weighted Average Grant-Date Stock Price, Options Exercisable	$ 4.70	$ 4.70

WARRANTS (Narrative) (Details)

WARRANTS (Narrative) (Details)

Sep. 10, 2014USD ($)

Sep. 09, 2014$ / sharesshares

Aug. 25, 2014USD ($)$ / sharesshares

May 31, 2016$ / sharesshares

May 31, 2015USD ($)$ / shares$ / securityshares

Jun. 30, 2016USD ($)$ / sharesshares

Jun. 30, 2015USD ($)

Mar. 31, 2016USD ($)$ / shares$ / securityshares

Mar. 31, 2015USD ($)$ / shares$ / securityshares

May 11, 2015USD ($)

Sep. 24, 2014USD ($)

Sep. 08, 2014$ / shares

Mar. 31, 2014$ / sharesshares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued as part of private placement

999,700

Exercise price of warrants | $ / shares

$ 0.55

$ 3.50

$ 3.90

$ 4.10

Warrants outstanding

9,702,718

2,002,718

1,212,718

772,717

Warrants issued (shares)

7,950,000

1,290,000

807,648

Cost to induce exercise of warrants | $

$ 21,218

$ (961,767)

Derivative liability | $

$ 335,802

$ 401,127

1,406,596

$ 1,694,651

$ 961,767

Cost of warrant modification | $

961,767

Fair value of warrants accounted for as derivatives | $

$ 940,549

Stock-based compensation expense | $

24,000

$ 59,234

Aggregate intrinsic value of all outstanding and exercisable warrants | $

2,623,500

0

Common stock issued upon exercise of warrants, value | $

$ 100,000

1,470,588

Common stock issued upon exercise of warrants, shares

588,236

Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

440,000

Exercise price of warrants | $ / shares

$ 3

Warrant expiration period

10 years

Stock-based compensation expense | $

182,072

432,772

Unamortized cost of outstanding warrants | $

$ 21,000

$ 91,036

Share-based Compensation Award, Tranche One [Member] | Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

80,000

Warrant vesting description

vested immediately at their grant date

Stock-based compensation expense | $

$ 201,680

Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

200,000

Fair value of warrants vesting | $

$ 504,204

Stock-based compensation expense | $

$ 35,014

Share-based Compensation Award, Tranche Three [Member] | Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

160,000

Warrant vesting description

vest upon achievement of certain milestones under the distribution agreement (See Note 9)

Minimum [Member] | Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period of warrants

1 year

Maximum [Member] | Share-based Compensation Award, Tranche Two [Member] | Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period of warrants

3 years

Replacement Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

367,647

Exercise price of warrants | $ / shares

$ 4.50

Cost to induce exercise of warrants | $

$ 940,549

Warrant expiration period

5 years

Minumum exercise price for automatic reset provision | $ / security

2

Early Exercise Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

367,647

Exercise price of warrants | $ / shares

$ 4

$ 4.20

Warrants outstanding

367,647

Cost to induce exercise of warrants | $

$ 21,218

Warrant expiration period

9 months

Placement Agent Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

40,000

Exercise price of warrants | $ / shares

$ 3.75

Exercise term of warrants issued

5 years

Warrant expiration period

5 years

Securities Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued as part of private placement

2,650,000

500,000

Number of shares called by exercise of warrants

7,950,000

1,250,001

Exercise price of warrants | $ / shares

$ 0.17

Shares issued, price per share | $ / shares

$ 0.10

$ 3

Exercise term of warrants issued

6 months

Derivative liability | $

$ 401,127

Securities Purchase Agreement Warrants, Series A [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

500,000

Exercise price of warrants | $ / shares

$ 4.50

Exercise term of warrants issued

5 years

Warrant expiration period

5 years

Minumum exercise price for automatic reset provision | $ / security

2

2

Securities Purchase Agreement Warrants, Series B [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

500,000

Exercise price of warrants | $ / shares

$ 3.50

Exercise term of warrants issued

9 months

Warrant expiration period

9 months

Securities Purchase Agreement Warrants, Series C [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

250,000

Exercise price of warrants | $ / shares

$ 4

Exercise term of warrants issued

1 year

Warrant expiration period

1 year

WARRANTS (Summary of Warrants t

WARRANTS (Summary of Warrants to Purchase Common Stock Issued) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
WARRANTS [Abstract]
Shares, Beginning balance	2,002,718	1,212,718	772,717
Shares, Granted	7,950,000	1,290,000	807,648
Shares, Exercised			(367,647)
Shares, Cancelled	250,000	(500,000)
Shares, Balance	9,702,718	2,002,718	1,212,718
Shares, exercisable		2,002,718
Weighted Average Exercise Price, Beginning balance	$ 3.50	$ 3.90	$ 4.10
Weighted Average Exercise Price, Granted	0.17	3.40	3.70
Weighted Average Exercise Price, Exercised			4
Weighted Average Exercise Price, Cancelled	4	3.50
Weighted Average Exercise Price, Balance	0.55	3.50	3.90
Weighted Average Exercise Price, Exercisable Balance		3.50
Exercise price of warrants subject to contingent adjustment	$ 3.50	$ 3.90	$ 4.10

INCOME TAXES (Details)

INCOME TAXES (Details)	Mar. 31, 2016USD ($)
INCOME TAXES [Abstract]
Net operating loss carry forwards	$ 8,900,000
Liability for unrecognized tax benefits	$ 0

DISTRIBUTION AND LICENSE AGRE44

DISTRIBUTION AND LICENSE AGREEMENTS (Details) - shares	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2014	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Aug. 25, 2014
Warrants issued (shares)		7,950,000	1,290,000	807,648
Employment Contracts [Member]
Number of shares called by exercise of warrants					440,000
Employment Contracts [Member] | Share-based Compensation Award, Tranche One [Member]
Warrant vesting terms description			vested immediately at their grant date
Number of shares called by exercise of warrants					80,000
Employment Contracts [Member] | Share-based Compensation Award, Tranche Two [Member]
Number of shares called by exercise of warrants					200,000
Employment Contracts [Member] | Share-based Compensation Award, Tranche Three [Member]
Warrant vesting terms description			vest upon achievement of certain milestones under the distribution agreement (See Note 9)
Number of shares called by exercise of warrants					160,000
Qualipride International [Member] | Maximum [Member]
Handling charge, percent of product cost			2.00%
Sales commission charge as percent of product cost			5.00%
Qualipride International [Member] | Employment Contracts [Member]
Stock-based compensation, shares issued during period	240,000
Number of shares called by exercise of warrants	440,000
Qualipride International [Member] | Employment Contracts [Member] | Share-based Compensation Award, Tranche One [Member]
Number of warrants or shares vested	40,000
Warrant vesting terms description			vested immediately upon issuance
Number of shares called by exercise of warrants	80,000
Qualipride International [Member] | Employment Contracts [Member] | Share-based Compensation Award, Tranche Two [Member]
Number of warrants or shares vested	100,000
Number of shares called by exercise of warrants	200,000
Qualipride International [Member] | Employment Contracts [Member] | Share-based Compensation Award, Tranche Three [Member]
Number of warrants or shares vested	100,000
Warrant vesting terms description			will vest once we achieve certain financial and operational milestones
Number of shares called by exercise of warrants	160,000
Qualipride International [Member] | Employment Contracts [Member] | Minimum [Member] | Share-based Compensation Award, Tranche Two [Member]
Vesting period of options or warrants granted	1 year
Qualipride International [Member] | Employment Contracts [Member] | Maximum [Member] | Share-based Compensation Award, Tranche Two [Member]
Vesting period of options or warrants granted	3 years

RELATED PARTY TRANSACTIONS AN45

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Aug. 22, 2012	Apr. 23, 2012
Operating Leased Assets [Line Items]
Operating leases, net rent expense	$ 0	$ 10,900	$ 30,600	$ 49,000
Carlson Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month	$ 2,300		2,300
Security deposit						$ 1,500
Sacramento Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month			$ 1,000
Security deposit					$ 1,000

COMMITMENTS (Details)

COMMITMENTS (Details) - Licensing Agreements [Member]	12 Months Ended
	Mar. 31, 2016USD ($)
Maximum proceeds from patent prosecution cost	$ 50,000
Minimum annual royalty pursuant to license agreement, year three and beyond	$ 10,000
Royalties owed as percent of sale price of products developed using licensed intellectual property	0.50%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Jul. 31, 2016	May 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Oct. 11, 2011	Oct. 09, 2011
Subsequent Event [Line Items]
Issuance of stock and warrants, shares		999,700
Issuance of stock and warrants, value		$ 99,970	$ 165,030
Options granted				275,000	135,000
Exercise price of warrants			$ 0.55	$ 3.50	$ 3.90	$ 4.10
Common stock, shares authorized			1,000,000,000	1,000,000,000	1,000,000,000		525,000,000	75,000,000
Employees [Member]
Subsequent Event [Line Items]
Options granted during period (shares)				137,500	112,500
Grant-date fair value of options granted				$ 233,000	$ 300,000
Expiration period of options granted				10 years	10 years
Expected volatility rate of options granted				76.26%	81.84%
Expected discount rate of options granted				2.19%	1.62%
Expected dividend yield of options granted				0.00%	0.00%
Expected life of options granted				5 years	5 years
Consultants [Member]
Subsequent Event [Line Items]
Options granted during period (shares)				140,000	22,500
Grant-date fair value of options granted				$ 131,000	$ 88,000
Expected volatility rate of options granted					76.26%
Expected discount rate of options granted				2.17%	2.17%
Expected dividend yield of options granted				0.00%	0.00%
Expected life of options granted				5 years	5 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of stock and warrants, shares		2,650,000
Number of shares called by exercise of warrants		7,950,000
Exercise price of warrants		$ 0.17
Shares issued, price per share		$ 0.10
Proceeds from Issuance of Warrants		$ 265,000
Exercise term of warrants issued		6 months
Subsequent Event [Member] | Employees [Member]
Subsequent Event [Line Items]
Options granted during period (shares)	1,525,703
Grant-date fair value of options granted	$ 365,330
Expiration period of options granted	10 years
Vesting period of options or warrants granted	24 months
Expected volatility rate of options granted	126.34%
Expected discount rate of options granted	1.60%
Expected dividend yield of options granted	0.00%
Expected life of options granted	5 years
Options granted, exercise price	$ 0.50
Subsequent Event [Member] | Consultants [Member]
Subsequent Event [Line Items]
Options granted during period (shares)	185,118
Grant-date fair value of options granted	$ 44,326
Expiration period of options granted	10 years
Vesting period of options or warrants granted	24 months
Expected volatility rate of options granted	126.34%
Expected discount rate of options granted	1.60%
Expected dividend yield of options granted	0.00%
Expected life of options granted	5 years
Options granted, exercise price	$ 0.50
Subsequent Event [Member] | Restricted Common Stock [Member] | CEO and Chairman of Board of Directors [Member]
Subsequent Event [Line Items]
Issuance of stock and warrants, shares	1,436,170
Issuance of stock and warrants, value	$ 718,015
Vesting period of options or warrants granted	20 months